Cocrystal Pharma Inc
COCP
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.86M
Close$
$0.49
54.7% downside
Current Fair Value
54.7% downsideOvervalued by 54.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.86 Million |
|---|---|
| Enterprise Value | $15.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.78 |
| Beta | 1.43 |
| Outstanding Shares | 13,788,000 |
Return
| Return on Equity | -951.92% |
|---|---|
| Return on Assets | -213.77% |
| Return on Invested Capital | -498.92% |
Valuation & Multiples
| P/E Ratio | -1.49 |
|---|---|
| PEG | -2.77 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 143.12 |
| Enterprise Value to EBIT | -1.48 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 1.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$105,000
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$105,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.63%▼ 1.19% |
|---|---|
| Total Invested | $783,754▲ 3.90% |
| Investors Holding | 25▼ 1.00% |
ESG Score
No data
About Cocrystal Pharma Inc
CEO: Gary Wilcox